QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NASDAQ:HOTH

Hoth Therapeutics Stock Forecast, Price & News

$0.81
-0.01 (-1.22%)
(As of 12/1/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.81
$0.88
50-Day Range
$0.81
$1.23
52-Week Range
$0.78
$3.50
Volume
239,583 shs
Average Volume
1.85 million shs
Market Capitalization
$19.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1
30 days | 90 days | 365 days | Advanced Chart
Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Hoth Therapeutics logo

About Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOTH
Fax
N/A
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.35 per share

Profitability

Net Income
$-7.20 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,087,000
Market Cap
$19.44 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

0.98 out of 5 stars

Medical Sector

1269th out of 1,392 stocks

Pharmaceutical Preparations Industry

612th out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

How has Hoth Therapeutics' stock been impacted by COVID-19?

Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOTH shares have decreased by 78.9% and is now trading at $0.8110.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 236,400 shares, an increase of 34.2% from the October 31st total of 176,100 shares. Based on an average trading volume of 328,500 shares, the short-interest ratio is currently 0.7 days. Approximately 1.3% of the shares of the company are sold short.
View Hoth Therapeutics' Short Interest
.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Hoth Therapeutics
.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its earnings results on Wednesday, November, 10th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01.
View Hoth Therapeutics' earnings history
.

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the following people:
  • Robbie Knie, Chairman, President & Chief Executive Officer
  • Hayley Springer, Vice President-Operations
  • David S. Briones, Chief Financial & Accounting Officer
  • Stefanie Johns, Chief Scientific Officer
  • MaryBeth Jones, Director-Project Management

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu Biopharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Who are Hoth Therapeutics' major shareholders?

Hoth Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.50%) and Bank of New York Mellon Corp (0.16%).
View institutional ownership trends for Hoth Therapeutics
.

Which institutional investors are buying Hoth Therapeutics stock?

HOTH stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Hoth Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $0.81.

How much money does Hoth Therapeutics make?

Hoth Therapeutics has a market capitalization of $19.44 million. The company earns $-7.20 million in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Hoth Therapeutics have?

Hoth Therapeutics employs 4 workers across the globe.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is www.hoththerapeutics.com.

Where are Hoth Therapeutics' headquarters?

Hoth Therapeutics is headquartered at 1 Rockefeller Plaza Suite 1039, New York NY, 10020.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at (646) 756-2997 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.